| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/12/2012 | US20120009256 Treatment Including Prebiotic Composition for use with Probiotics |
| 01/12/2012 | US20120009255 Methods of treating infectious diseases |
| 01/12/2012 | US20120009254 Respiratory Syncytial Virus Antigenic Compositions and Methods |
| 01/12/2012 | US20120009253 Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds of the lower respiratory tract |
| 01/12/2012 | US20120009252 Liposomal formulations of anthracycline agents and cytidine analogs |
| 01/12/2012 | US20120009251 Cholestanol derivative for combined use |
| 01/12/2012 | US20120009250 Controlled release delivery system for nasal applications |
| 01/12/2012 | US20120009249 Controlled release delivery system for nasal application of neurotransmitters |
| 01/12/2012 | US20120009248 Preservation of Bioactive Materials By Spray Drying |
| 01/12/2012 | US20120009247 Phospholipid drug analogs |
| 01/12/2012 | US20120009246 Phospholipid-analogous compounds |
| 01/12/2012 | US20120009245 Administration of Growth Factors for the Treatment of CNS Disorders |
| 01/12/2012 | US20120009244 NEUROD1 GENE EXPRESSION IN NON-ENDOCRINE PANCREATIC EPITHELIAL CELLS (NEPECs) |
| 01/12/2012 | US20120009243 Liposomes for drug delivery and methods for preparation thereof |
| 01/12/2012 | US20120009241 Skin wound dressing and preparing method thereof |
| 01/12/2012 | US20120009240 Films for Delivery of a Therapeutic Agent |
| 01/12/2012 | US20120009239 Prebiotic Formulations for use with Probiotics to Increase Probiotic Growth Rate and Activity |
| 01/12/2012 | US20120009237 Wound healing compositions containing keratin biomaterials |
| 01/12/2012 | US20120009231 Apparatus and method for deposition of functional coatings |
| 01/12/2012 | US20120009229 Pharmaceutical compositions and related methods of delivery |
| 01/12/2012 | US20120009228 Prebiotic Compositions for use with Probiotics to Increase Probiotic Growth Rate and Activity |
| 01/12/2012 | US20120009227 Active coating of pharmaceutical dosage forms |
| 01/12/2012 | US20120009226 Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| 01/12/2012 | US20120009225 Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration |
| 01/12/2012 | US20120009224 Particulate cartilage treatment composition |
| 01/12/2012 | US20120009223 COLLAGEN-BASED HYDROGELS LOADED WITH ZnO QDs/pDNA COMPLEXES AS CORNEAL SUBSTITUES |
| 01/12/2012 | US20120009167 Solid composition containing bacillus-type non-pathogenic bacterial spores |
| 01/12/2012 | US20120009131 Method for preventing or treating amyloid beta peptide-associated diseases or conditions, and method for inhibiting formation, accumulation or aggregation of amyloid beta peptides |
| 01/12/2012 | US20120009130 Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques |
| 01/12/2012 | US20120009129 Pharmaceutical compositions for deterring misuse, abuse, and diversion |
| 01/12/2012 | US20120009128 Preservative system and composition based on glycinate and hydroxyethyl sulfonate salt combination |
| 01/12/2012 | US20120009127 Foam enhancement of fatty acyl glycinate surfactants |
| 01/12/2012 | US20120006323 Nasal devices |
| 01/12/2012 | DE112009001815T5 Herstellungsverfahren für bioabbaubare Mikropartikel, welche Arzneistoffe enthalten Contain manufacturing method for biodegradable microparticles which drugs |
| 01/12/2012 | DE102010026903A1 Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff Transdermal therapeutic system with avocado oil or palm oil as an adjuvant |
| 01/12/2012 | DE102010026696A1 Use of a grease pencil for medical application of active ingredients on the edge of the eyelid, for e.g. treating allergic diseases of the eye, changes in intraocular pressure, preferably glaucoma, and inflammations of the eye |
| 01/12/2012 | CA2805568A1 Oral dosage form of deferasirox |
| 01/12/2012 | CA2804989A1 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| 01/12/2012 | CA2804926A1 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
| 01/12/2012 | CA2804874A1 Formulations comprising coated fine particles |
| 01/12/2012 | CA2804815A1 Nucleic acid delivery composition and carrier composition, pharmaceutical composition using the same, and method for nucleic acid delivery |
| 01/12/2012 | CA2804601A1 Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides |
| 01/12/2012 | CA2804591A1 Cationic oil-in-water emulsions |
| 01/12/2012 | CA2804506A1 Formulation for co-therapy treatment of diabetes |
| 01/12/2012 | CA2804504A1 Intraorally disintegrating tablet |
| 01/12/2012 | CA2804477A1 Stable aqueous formulations comprising poorly water soluble active ingredients |
| 01/12/2012 | CA2804396A1 Liposomes with lipids having an advantageous pka-value for rna delivery |
| 01/12/2012 | CA2804358A1 Pharmaceutical compositions containing vanoxerine |
| 01/12/2012 | CA2804341A1 Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration |
| 01/12/2012 | CA2804337A1 Dry compositions and devices containing such dry compositions for use in photodynamic therapy or photodynamic diagnosis |
| 01/12/2012 | CA2804124A1 Cannabis drug delivery and monitoring system |
| 01/12/2012 | CA2803064A1 Dosage form |
| 01/12/2012 | CA2803004A1 Oral formulation of kinase inhibitors |
| 01/12/2012 | CA2802443A1 Vaccine compositions based on sticholysin encapsulated in liposomes |
| 01/12/2012 | CA2801620A1 Novel gastro-retentive dosage forms comprising a gaba analog and an opioid |
| 01/12/2012 | CA2800679A1 Compositions and methods for enhancement of nucleic acid delivery |
| 01/11/2012 | EP2405001A1 Nucleic acid complex and nucleic acid-delivering composition |
| 01/11/2012 | EP2404932A1 Polypeptides and antibacterial or antiseptic use of same |
| 01/11/2012 | EP2404619A1 Injectable composition composed of an injectable medication and a gel |
| 01/11/2012 | EP2404606A1 Ophthalmic compositions comprising a prostaglandin and a viscosity agent |
| 01/11/2012 | EP2404605A1 Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
| 01/11/2012 | EP2404598A1 Amino acid-conjugated cyanoacrylate polymer particles |
| 01/11/2012 | EP2404594A1 Compositions comprising docetaxel with increased stability and methods for preparation thereof |
| 01/11/2012 | EP2404593A1 Composition containing quaternary ammonium compounds |
| 01/11/2012 | EP2404588A1 Package of solid pharmaceutical preparation |
| 01/11/2012 | EP2403937A2 Methods of inhibiting photoreceptor apoptosis |
| 01/11/2012 | EP2403701A1 Starch foils or films, and method and apparatus for the production thereof |
| 01/11/2012 | EP2403700A1 Starch-based soft capsule, and method and apparatus for the production thereof |
| 01/11/2012 | EP2403551A2 Silk fibroin systems for antibiotic delivery |
| 01/11/2012 | EP2403520A1 Insulin formulations for rapid uptake |
| 01/11/2012 | EP2403504A1 Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties |
| 01/11/2012 | EP2403500A2 Stable olanzapine tablets and the process for its preparation |
| 01/11/2012 | EP2403493A2 Non-steroidal anti-inflammatory ophthalmic compositions |
| 01/11/2012 | EP2403490A2 An improved dry powder drug delivery system |
| 01/11/2012 | EP2403489A1 Organic chewable supplement |
| 01/11/2012 | EP2403488A2 Controlled-release ophthalmic vehicles |
| 01/11/2012 | EP2403487A2 Oral controlled release dosage forms for water soluble drugs |
| 01/11/2012 | EP2403486A1 Sustained release oral dosage forms of an r-baclofen prodrug |
| 01/11/2012 | EP2403485A2 Pharmaceutical composition containing rasagiline mesylate |
| 01/11/2012 | EP2403484A2 Pharmaceutical composition containing a fermented, dehydrated material with amorphous crystalline structure |
| 01/11/2012 | EP2403483A2 Injectable biomaterial |
| 01/11/2012 | EP2403482A1 Abuse resistant formulation |
| 01/11/2012 | EP2403481A1 Oral dosage forms having a high loading of a gabapentin prodrug |
| 01/11/2012 | EP2403480A1 A process to make fusidic acid cream |
| 01/11/2012 | EP2403479A1 Resveratrol compositions for use as dietary supplements |
| 01/11/2012 | EP2403478A1 Anionic oil-in-water emulsions containing prostaglandins and uses thereof |
| 01/11/2012 | EP2403477A1 Cationic oil-in-water emulsions containing prostaglandins and uses thereof |
| 01/11/2012 | EP2403476A1 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail |
| 01/11/2012 | EP2403475A2 Delivery system |
| 01/11/2012 | EP2403446A1 Pad with fluid barrier |
| 01/11/2012 | EP2403445A1 Soft edged pad |
| 01/11/2012 | EP2403335A1 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 01/11/2012 | EP2142178B1 Pharmaceutical composition and process |
| 01/11/2012 | EP2066325B1 Pharmaceutical compositions of aripiprazole |
| 01/11/2012 | EP2007197B1 Adherence-aided therapeutic horse hoof packing |
| 01/11/2012 | EP1946780B1 Controlled release solid preparation |
| 01/11/2012 | EP1653927B1 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 01/11/2012 | EP1572074B1 Stabilized synthetic immunogen delivery system |
| 01/11/2012 | EP1511845B1 Immunostimulatory oligonucleotides and uses thereof |
| 01/11/2012 | CN202105203U Sticking membrane for dermatosis and ulcer wound surface |